Last reviewed · How we verify
Vorolanib Tablets+Everolimus
Vorolanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs), and Everolimus is an mTOR inhibitor.
Vorolanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs), and Everolimus is an mTOR inhibitor. Used for Non-small cell lung cancer, Renal cell carcinoma.
At a glance
| Generic name | Vorolanib Tablets+Everolimus |
|---|---|
| Sponsor | Peking University Cancer Hospital & Institute |
| Drug class | tyrosine kinase inhibitor |
| Target | VEGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Vorolanib works by inhibiting the VEGF signaling pathway, which is involved in angiogenesis and tumor growth. Everolimus, on the other hand, inhibits the mTOR pathway, which is involved in cell proliferation and survival.
Approved indications
- Non-small cell lung cancer
- Renal cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Leukopenia
Key clinical trials
- A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI (PHASE3)
- CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma (PHASE3)
- Study of the Combination of CM082 With Everolimus in Patients With mRCC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |